- Home
- STTK vs ISPR Comparison
STTK vs ISPR Comparison
Compare STTK & ISPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ISPR
- Stock Information
- Founded
- STTK 2016
- ISPR 2010
- Country
- STTK United States
- ISPR United States
- Employees
- STTK N/A
- ISPR N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ISPR Medicinal Chemicals and Botanical Products
- Sector
- STTK Health Care
- ISPR Health Care
- Exchange
- STTK Nasdaq
- ISPR Nasdaq
- Market Cap
- STTK 112.6M
- ISPR 126.0M
- IPO Year
- STTK 2020
- ISPR 2023
- Fundamental
- Price
- STTK $1.98
- ISPR $2.44
- Analyst Decision
- STTK Hold
- ISPR Strong Buy
- Analyst Count
- STTK 5
- ISPR 1
- Target Price
- STTK $3.00
- ISPR $7.50
- AVG Volume (30 Days)
- STTK 411.4K
- ISPR 51.0K
- Earning Date
- STTK 11-13-2025
- ISPR 11-10-2025
- Dividend Yield
- STTK N/A
- ISPR N/A
- EPS Growth
- STTK N/A
- ISPR N/A
- EPS
- STTK N/A
- ISPR N/A
- Revenue
- STTK $2,997,000.00
- ISPR $127,494,304.00
- Revenue This Year
- STTK N/A
- ISPR $60.96
- Revenue Next Year
- STTK N/A
- ISPR $23.96
- P/E Ratio
- STTK N/A
- ISPR N/A
- Revenue Growth
- STTK N/A
- ISPR N/A
- 52 Week Low
- STTK $0.69
- ISPR $2.06
- 52 Week High
- STTK $2.71
- ISPR $7.47
- Technical
- Relative Strength Index (RSI)
- STTK 48.57
- ISPR 44.98
- Support Level
- STTK $1.72
- ISPR $2.33
- Resistance Level
- STTK $2.71
- ISPR $2.45
- Average True Range (ATR)
- STTK 0.22
- ISPR 0.20
- MACD
- STTK -0.09
- ISPR 0.01
- Stochastic Oscillator
- STTK 25.05
- ISPR 48.72
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.